FDA Advisors Vote That Benefits Of Abbott’s MitraClip Outweigh Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency’s Circulatory System Devices Panel narrowly voted in favor of Abbott’s MitraClip transcatheter mitral valve repair system to reduce mitral regurgitation. But the discussions about the clinical evidence on the technology were complex and the panel’s support for Abbott’s PMA was not unanimous.
You may also be interested in...
FDA Advisory Panel Will Evaluate Abbott’s MitraClip Next Month
Abbott to present data showing MitraClip is safer option for inoperable patients.
Four Firms Vie For Medicare 2014 New-Tech Add-On Payments
CMS held its annual new-technology Town Hall Feb. 5, hearing from applicants for a drug-eluting peripheral artery stent, a neurostimulator system for epilepsy seizures, a transcatheter mitral valve repair system and a retinal prosthesis system.
Louis Jacques On Coverage, Evidence And IDEs
Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.